

Simcere: Pioneer the healthcare frontier

Simcere is an integrated pharmaceutical group with leading development and commercial capabilities in China. Simcere is an emerging leader in R&D of innovative medicines and branded generics in China focusing on oncology, neurology, cardiovascular & metabolic diseases, Inflammation and Infectious diseases. In 2015, Simcere's translational medicine and innovative drug R&D platform has been recognized as a State Key Laboratory by the National Ministry of Science and Technology. Simcere has also been actively pursuing cross-border partnerships to bringing global innovation and brands to China. Simcere has been nominated as top 100 in China pharmaceutical industry and top 10 most innovative companies in China for many years. Simcere of America has set up two offices, in Boston——international business development, New Jersey——international pharmaceutical business development.

BioSciKin: Help more people with precision medicine

BioSciKin is a China-based biotechnology company focusing on precision medicine, drug innovation, incubation, and investment. It is recognized by State Ministry of China as a National Start-up Space. BSK is developing innovative precision medicine products, and is looking for partnership from all over the world for investment and co-development opportunities. We have formed strong alliances with multiple global ventures and invested over 20 start-up companies world-wide.

Looking into the future, our aim is to build:

- An open investment and incubation platform of precision medicine
- A leading precision medicine clinical test laboratory
- A pioneer in innovative drug development and commercialization

**转化医学与创新药物
国家重点实验室**
(2015年-2020年)

中华人民共和国科学技术部



Wechat and email dongguowei@simcere.com



中华人民共和国科学技术部